Stężenia adipokin u mężczyzn z rakiem prostaty i z łagodnym przerostem prostaty

Siemińśka, Lucyna; Borowski, Artur; Marek, Bogdan; Nowak, Mariusz; Kajdaniuk, Dariusz; Warakomski, Jakub; Kos–Kudła, Beata

doi:10.5603/ep.a2018.0006

Cited by 17 publications

(15 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…in vitro, genetic studies), and a further 15 were trials with no control groups, repeat publications or abstracts. 5 studies were eligible [62][63][64][65][66] . The albatross plots 26 in Supplementary Fig.…”

Section: In Each Main Analysis)mentioning

confidence: 99%

Circulating adiponectin and leptin and risk of overall and aggressive prostate cancer: a systematic review and meta-analysis

Burton

Gilbert

Tilling

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Obesity is associated with an increased risk of advanced, recurrent and fatal prostate cancer. Adipokines may mediate this relationship. We conducted a systematic review and meta-analysis of associations of leptin and adiponectin with overall and aggressive prostate cancer. Bibliographic databases were systematically searched up to 1st April 2017. Log Odds Ratios (ORs) per 2.5 unit increase in adiponectin or leptin levels were derived and pooled. All analyses were stratified by study type (cross-sectional/prospective). 746 papers were retrieved, 34 eligible studies identified, 31 of these could be included in the meta-analysis. Leptin was not consistently associated with overall prostate cancer (pooled OR 1.00, 95%CI 0.98–1.02, per 2.5 ng/ml increase, prospective study OR 0.97, 95%CI 0.95–0.99, cross-sectional study OR 1.19, 95%CI 1.13–1.26) and there was weak evidence of a positive association with aggressive disease (OR 1.03, 95%CI 1.00–1.06). There was also weak evidence of a small inverse association of adiponectin with overall prostate cancer (OR 0.96, 95%CI 0.93–0.99, per 2.5 µg/ml increase), but less evidence of an association with aggressive disease (OR 0.98, 95%CI 0.94–1.01). The magnitude of any effects are small, therefore levels of circulating adiponectin or leptin alone are unlikely to be useful biomarkers of risk or prognosis.

show abstract

Section: In Each Main Analysis)mentioning

confidence: 99%

Circulating adiponectin and leptin and risk of overall and aggressive prostate cancer: a systematic review and meta-analysis

Burton

Gilbert

Tilling

et al. 2021

Sci Rep

View full text Add to dashboard Cite

show abstract

“…No significant difference in serum chemerin concentration was found between patients with prostate cancer and those with benign prostatic hyperplasia, however, differences were identified between cancer patients with different Gleason scores, a progressive measurement of prostate cancer aggressiveness as determined by tumor cell differentiation [72]. Serum chemerin concentration was observed to increase with Gleason score, where tumors with a score of ≥8, 7, and ≤6 were significantly different from one another [72]. There was also a positive correlation between the serum levels of chemerin and IL-6 [72].…”

Section: Prostate Cancermentioning

confidence: 99%

“…Serum chemerin concentration was observed to increase with Gleason score, where tumors with a score of ≥8, 7, and ≤6 were significantly different from one another [72]. There was also a positive correlation between the serum levels of chemerin and IL-6 [72]. Comparing non-obese to obese patients with prostate cancer who subsequently underwent radical prostatectomy, there was no significant difference found in serum chemerin concentration based on BMI prior to surgery (Table 1) [73].…”

Section: Prostate Cancermentioning

confidence: 99%

More Than an Adipokine: The Complex Roles of Chemerin Signaling in Cancer

Goralski

Jackson

McKeown

et al. 2019

IJMS

View full text Add to dashboard Cite

Chemerin is widely recognized as an adipokine, with diverse biological roles in cellular differentiation and metabolism, as well as a leukocyte chemoattractant. Research investigating the role of chemerin in the obesity–cancer relationship has provided evidence both for pro- and anti-cancer effects. The tumor-promoting effects of chemerin primarily involve direct effects on migration, invasion, and metastasis as well as growth and proliferation of cancer cells. Chemerin can also promote tumor growth via the recruitment of tumor-supporting mesenchymal stromal cells and stimulation of angiogenesis pathways in endothelial cells. In contrast, the majority of evidence supports that the tumor-suppressing effects of chemerin are immune-mediated and result in a shift from immunosuppressive to immunogenic cell populations within the tumor microenvironment. Systemic chemerin and chemerin produced within the tumor microenvironment may contribute to these effects via signaling through CMKLR1 (chemerin1), GPR1 (chemerin2), and CCLR2 on target cells. As such, inhibition or activation of chemerin signaling could be beneficial as a therapeutic approach depending on the type of cancer. Additional studies are required to determine if obesity influences cancer initiation or progression through increased adipose tissue production of chemerin and/or altered chemerin processing that leads to changes in chemerin signaling in the tumor microenvironment.

show abstract

“…Furthermore, prostate cancer patients showed higher levels of this cytokine compared to a healthy control group. Moreover, it positively correlated with a higher Gleason score (Siemińska et al, 2015). In metastatic prostate cancer patients, the serum level of IL-6 was higher than in patients with localized disease; hence it may serve as a prognostic factor (Michalaki et al, 2004).…”

Section: Discussionmentioning

confidence: 92%

Cytokine IL6, but not IL-1β, TNF-α and NF-κB is increased in paediatric cancer patients

Synakiewicz

Stanisławska-Sachadyn

Owczarzak

et al. 2023

Acta Biochim Pol

View full text Add to dashboard Cite

Cytokines are responsible for maintaining homeostasis as cell growth, differentiation, migration and apoptosis mediators. They play a pivotal role in immune responses to inflammatory reactions. In oncological diseases, the cross-talk between cells of the immunological system and cells of the tumour microenvironment is led by cytokines. Also, the overproduction of cytokines may change the tumour microenvironment and stimulate tumour development and growth. To test whether pro-inflammatory cytokines or associated with them transcription factor levels are changed in a group of 53 paediatric cancer patients, serum levels of IL-1β, IL-6, TNF-α and NF-κB were assessed and compared to measures in 25 healthy controls. Increased levels of IL-6 were found among patients in active oncological treatment (P=0.002) but not among patients whose treatment was completed. Our data suggest that IL6, but not IL-1β, TNF-α and NF-κB, is elevated as a result of the immune response in the microenvironment around the tumour and in blood cancers, among patients who were not infected at the time of blood collection. Thus, IL6 levels might serve as a potential biomarker of oncohematological diseases.

show abstract

Stężenia adipokin u mężczyzn z rakiem prostaty i z łagodnym przerostem prostaty

Abstract: Leptin-to-adiponectin ratio and IL-6 were elevated in men with prostate cancer. Leptin, chemerin and IL-6 were associated with Gleason score. The relationships between leptin, chemerin and IL-6 were dependent on each other. Overweight and obese men had a higher Gleason score.

Cited by 17 publications

References 36 publications

Circulating adiponectin and leptin and risk of overall and aggressive prostate cancer: a systematic review and meta-analysis

Circulating adiponectin and leptin and risk of overall and aggressive prostate cancer: a systematic review and meta-analysis

More Than an Adipokine: The Complex Roles of Chemerin Signaling in Cancer

Cytokine IL6, but not IL-1β, TNF-α and NF-κB is increased in paediatric cancer patients

Contact Info

Product

Resources

About